PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome: These findings complement the above discussion of the importance of identifying additional biomarkers and screening criteria to identify patients who may benefit from PARP inhibitors, but may not express the typical mutation profile seen in HRD.